Psilocybin mushrooms have extremely low physical toxicity. The estimated lethal dose is around 6 grams of pure psilocybin, which is roughly 1,000 times the threshold dose and would require eating about 10 kilograms (22 pounds) of fresh mushrooms. Only three deaths in medical literature have been attributed directly to psilocybin mushroom toxicity. That said, “shrooms” are not without real risks, and the biggest danger often has nothing to do with psilocybin itself.
Why a Lethal Overdose Is Essentially Impossible
A typical dose of psilocybin ranges from 3 to 30 milligrams, corresponding to roughly 5 to 50 grams of fresh mushrooms. The estimated lethal dose sits at approximately 6,000 milligrams of the pure compound. To reach that through eating whole mushrooms, you would need to consume around 22 pounds of fresh material. Long before absorbing anything close to a dangerous amount, vomiting would prevent further intake. For comparison, psilocybin carries a lower risk of fatal overdose than virtually every other commonly used psychoactive substance, including cannabis and caffeine.
Common Physical Side Effects
Psilocybin does cause short-term physical effects, though they’re typically mild and resolve on their own. A 2024 meta-analysis in JAMA Network Open found that nausea, headache, dizziness, anxiety, and elevated blood pressure all occurred significantly more often with psilocybin than with placebo. Nausea showed up in 4% to 48% of participants across studies, with higher doses producing more nausea. In five of six studies reviewed, it resolved within 60 minutes.
Headaches were the other consistent side effect, reported in 2% to 66% of participants depending on the study. They were generally mild to moderate and cleared within 24 hours without medication. Blood pressure increases were more notable: in one trial, 34% of participants experienced systolic blood pressure above 160 mmHg at a high dose. Elevated heart rate was common but not considered medically serious, peaking around 84 beats per minute and normalizing within a day.
Kidney and Liver Effects
Psilocybin is not known to be toxic to the liver or kidneys in normal use. However, one documented case in the medical literature describes a 15-year-old who developed acute kidney injury 36 hours after eating Psilocybe cubensis mushrooms. His kidney function markers rose to nearly four times the normal range, and he was hospitalized for five days. He recovered fully within three months, and his kidney function returned to normal. Notably, three other people who ate mushrooms from the same batch had no kidney problems at all.
Researchers suspect the kidney injury may have been caused by blood vessel constriction affecting blood flow to the kidneys rather than direct chemical damage from psilocybin. This appears to be a rare event, but it has been documented.
The Real Danger: Picking the Wrong Mushroom
The most serious physical risk associated with “shrooms” isn’t psilocybin. It’s accidentally eating a poisonous lookalike. Most psilocybin-containing species are small, brown, and unremarkable in appearance. They closely resemble species in the Galerina genus, which contain amatoxins, the same deadly compounds found in death cap mushrooms. Amatoxins cause severe liver and kidney failure and are responsible for the vast majority of mushroom-related deaths worldwide.
Since the 1960s, there have been numerous severe poisonings from people collecting Galerina species while looking for psilocybin mushrooms. Galerina typically grows on wood rather than soil or lawns, but there are rare reports of it growing in grass on buried wood, making the distinction even harder. Other amatoxin-containing genera, including certain Amanita, Lepiota, and Conocybe species, present similar risks. Misidentification is not a minor concern. It is the primary way people are seriously harmed or killed in connection with magic mushrooms.
Psychological Risks
While physical toxicity is low, the psychological effects deserve attention. Psilocybin is a powerful psychoactive substance, and a difficult experience can include intense anxiety, paranoid thinking, or transient psychotic-like symptoms. In controlled clinical trials, about 26% of participants experienced notable anxiety during high-dose sessions, and around 7% experienced brief paranoid ideation or disordered thinking.
Persistent psychosis triggered by psilocybin is rare. A large meta-analysis published in Molecular Psychiatry found the incidence of psychedelic-induced psychosis was 0.2% among healthy participants in clinical trials and 0.002% in population-level studies. The risk increases substantially for people with schizophrenia or a family history of psychotic disorders, where rates of lasting psychotic symptoms reached 3.8% in some study groups. Among those who did develop substance-induced psychotic episodes from any psychedelic, about 13% went on to be diagnosed with schizophrenia over a roughly 10-year follow-up period.
Interactions With Other Drugs
Psilocybin works primarily on serotonin receptors, which means combining it with other drugs that raise serotonin levels can create risk. Serotonin toxicity exists on a spectrum, from mild symptoms like agitation and rapid heartbeat to a life-threatening condition called serotonin syndrome, which involves muscle rigidity, dangerously high body temperature, and seizures.
The highest-risk combinations involve monoamine oxidase inhibitors (MAOIs), a class of antidepressants that dramatically increase serotonin availability. Combining psilocybin with an MAOI creates a meaningful risk of serotonin toxicity. SSRIs and other common antidepressants that don’t involve MAOIs appear to be lower risk in combination with psilocybin, though they can still blunt or alter the experience in unpredictable ways.
Addiction Potential
Psilocybin carries one of the lowest addiction risks of any psychoactive substance studied. In comparative analyses of dependence potential across drug categories, psilocybin ranked below caffeine for risk of developing dependence. Tobacco and heroin consistently rank at the top for likelihood of transitioning from use to dependence, while psychedelics like psilocybin and LSD sit at the very bottom. Psilocybin also builds rapid tolerance, meaning the same dose produces significantly diminished effects if taken on consecutive days, which naturally discourages compulsive repeated use.